Bioceres Crop Solutions (BIOX) AI Stock Analysis

• Market Cap: $77.77M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: -27.90%
• EPS Growth: -4194.67%
• Country: US
• Employees: 400
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -0.12
• Shares Outstanding: 63,228,237
• 10 Day Avg. Volume: 1,709,433
• 30 Day Avg. Volume: 1,077,044
• PEG Ratio: <0.01
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.85
• P/FCF Ratio: 8.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $2.00
• Price Target Upside: 62.60% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $1.00 ▼(-18.70% Downside)

Bioceres Crop Solutions faces significant challenges, primarily due to declining revenues and profitability issues, as reflected in its financial performance and valuation scores. Technical analysis indicates bearish momentum, further weighing on the stock. While the earnings call highlighted some improvements in gross margin and cost efficiency, these are overshadowed by revenue declines and debt concerns. The company's focus on profitability and liquidity is crucial for future resilience, but current market conditions and financial metrics suggest caution.

Positive Factors

Gross Margin Expansion

A sustained gross margin improvement to 47% reflects a durable shift to higher‑margin product mix and better cost of goods control. Maintaining margins above 40% can insulate profitability from revenue volatility and supports longer‑term cash generation and reinvestment capacity.

Adjusted EBITDA Improvement

A 61% rise in adjusted EBITDA from deliberate SG&A cuts shows management can extract leverage from the cost base. If sustained, this operational discipline improves break‑even economics, enhances cash flow conversion and raises resilience during cyclical revenue downturns.

Positive Free Cash Flow Growth

Consistent free cash flow growth signals the business is beginning to convert earnings into liquidity. Durable FCF supports debt servicing, targeted R&D or seed commercialization, and provides optionality to fund restructuring or strategic partnerships without immediate equity dilution.

Negative Factors

Revenue Decline and Segment Weakness

A meaningful and recurring top‑line decline, driven by Crop Protection and Seed segments, undermines scale economics and R&D payback timelines. Persistent revenue contraction reduces margin leverage, curtails reinvestment capacity and weakens competitive positioning over several quarters.

High Leverage and Debt Burden

Elevated net debt and a multi‑turn net debt/EBITDA ratio limit financial flexibility and increase refinancing risk if earnings remain depressed. Servicing large secured obligations constrains capital allocation, heightens vulnerability to interest or covenant shocks, and pressures long‑term strategic options.

Noteholder Litigation and Foreclosure Risk

Ongoing litigation with secured noteholders and a threatened foreclosure process present structural governance and asset‑loss risks. If resolved unfavorably, outcomes could force asset transfers, weaken collateral access, and materially impair operations and investor confidence for months to years.

Bioceres Crop Solutions Business Overview & Revenue Model

Company Description

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.

How the Company Makes Money

Bioceres Crop Solutions generates revenue through several key streams. First, it sells proprietary seed traits that are designed to improve crop performance and resistance to various stresses. Second, the company offers crop protection products, which include biological and chemical solutions aimed at safeguarding crops from pests and diseases. Additionally, Bioceres has developed partnerships with agricultural distributors and other industry players, which help expand its market reach and enhance its product offerings. The company also benefits from licensing agreements and collaborations in research and development, allowing it to capitalize on its innovations while sharing the financial risks associated with new product development. Overall, Bioceres' revenue model is built on a combination of direct sales, partnerships, and strategic collaborations that leverage its expertise in agricultural biotechnology.

Bioceres Crop Solutions Financial Statement Overview

Summary

Bioceres Crop Solutions faces challenges with declining revenue and profitability, as evidenced by negative net profit margins and revenue growth rates. The balance sheet reveals a high debt-to-equity ratio, which could be a risk factor. On the positive side, the company has shown improvement in free cash flow, which is crucial for sustaining operations and growth. Overall, while there are areas of concern, particularly in profitability and leverage, the company is making strides in cash flow management.

Income Statement

Bioceres Crop Solutions has experienced declining revenue growth, with a negative growth rate in the TTM period. The company also shows negative net profit margins, indicating ongoing profitability challenges. However, the gross profit margin remains relatively stable, suggesting some operational efficiency. The negative EBIT margin highlights difficulties in covering operating expenses.

Balance Sheet

The company's debt-to-equity ratio is over 1, indicating a higher reliance on debt financing, which could pose risks if not managed properly. The return on equity is negative, reflecting challenges in generating returns for shareholders. However, the equity ratio indicates a reasonable proportion of equity financing relative to total assets.

Cash Flow

Bioceres shows positive free cash flow growth in the TTM period, which is a positive sign for liquidity. The operating cash flow to net income ratio is low, suggesting that cash generation from operations is not strong relative to net income. However, the free cash flow to net income ratio is relatively high, indicating efficient cash conversion from earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	318.23M	333.30M	464.83M	419.45M	328.46M	206.70M
Gross Profit	124.48M	130.20M	181.59M	180.25M	126.44M	90.88M
EBITDA	17.14M	13.59M	55.45M	72.38M	47.91M	43.70M
Net Income	-52.83M	-51.80M	3.24M	18.78M	-7.20M	-6.87M
Balance Sheet
Total Assets	734.88M	763.65M	852.55M	818.06M	518.22M	394.59M
Cash, Cash Equivalents and Short-Term Investments	16.61M	34.74M	56.17M	60.05M	38.61M	46.78M
Total Debt	267.74M	276.61M	270.95M	257.41M	169.79M	174.58M
Total Liabilities	455.83M	468.43M	501.17M	487.56M	359.92M	304.30M
Stockholders Equity	249.38M	262.81M	315.30M	298.85M	127.61M	67.74M
Cash Flow
Free Cash Flow	36.54M	35.30M	18.93M	-19.97M	-26.51M	-20.13M
Operating Cash Flow	45.23M	49.91M	41.72M	2.59M	-17.52M	-6.21M
Investing Cash Flow	-7.67M	-6.13M	-28.73M	-25.73M	2.90M	-8.31M
Financing Cash Flow	-56.76M	-50.71M	-10.06M	32.95M	14.82M	7.36M

Bioceres Crop Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Negative. The current price of 1.23 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.53, and below the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.37 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOX.

Bioceres Crop Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
BIOX	49 Neutral	$77.77M	-1.34	-20.52%	―	-27.90%	-4194.67%
SEED	46 Neutral	$14.45M	-17.92	―	―	-21.82%	-104.92%
AVD	45 Neutral	$114.73M	-1.03	-40.84%	―	-4.29%	-276.74%
RKDA	45 Neutral	$3.10M	-0.61	-64.08%	―	-1.80%	15.74%
BHST	45 Neutral	$117.24M	-7.55	-200.22%	―	45.88%	43.12%
LVRO	45 Neutral	$120.33M	-0.31	―	―	―	―

Bioceres Crop Solutions Corporate Events

Bioceres Crop Solutions Calls January 30, 2026 Shareholder Meeting to Approve FY 2025 Accounts and Board Slate

On January 8, 2026, Bioceres Crop Solutions Corp. filed a Form 6-K announcing that it has convened its 2026 Annual General Meeting of shareholders for January 30, 2026, to be held in New York and accessible virtually. Shareholders of record as of January 5, 2026, are invited to vote on approving the consolidated financial statements for the fiscal year ended June 30, 2025, electing four directors—Federico Trucco, Duraiswami (“D”) Narain, Antonio Simon Vumbaca and Yogesh Mago—to serve until the 2027 annual meeting, and ratifying the appointment of Price Waterhouse & Co. S.R.L. as the company’s independent registered public accounting firm. The meeting will feature telephone and web-based access, underscoring Bioceres’ efforts to facilitate participation by its global investor base and to reaffirm its governance and audit framework under Cayman Islands law and U.S. reporting standards.

The most recent analyst rating on (BIOX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Revamps Finance Leadership and Board Ahead of 2026 AGM

On December 31, 2025, Bioceres Crop Solutions announced leadership changes, naming agribusiness veteran Ezequiel Simmermacher as chief financial officer effective January 5, 2025, and appointing experienced industry executive Duraiswami (“D”) Narain to its board of directors as of December 29, 2025, following the December 26, 2025 resignation of longtime director Natalia Zang. The reshaped leadership, which includes Narain assuming Zang’s former committee roles and chairing the audit committee, is expected to strengthen Bioceres’ financial stewardship and governance as it prepares proxy materials for mailing in January 2026 and seeks to maintain continuity by proposing the reappointment of its current board through the 2027 annual general meeting.

The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Agrees to Adjourned Foreclosure Sale Amid Noteholder Litigation

On December 18, 2025, Bioceres Crop Solutions Corp. reported that a New York State court, hearing a lawsuit brought by several noteholders over alleged defaults on convertible and non-convertible notes issued under 2022 note purchase agreements, partially granted the plaintiffs’ motion to protect pledged collateral and denied the company’s cross-motion to halt a planned foreclosure auction. The court ordered Bioceres and affiliated Pro Farm entities not to transfer or encumber any collateral securing the notes, and, following that decision, the noteholders proposed, and Bioceres agreed on December 20, 2025, to adjourn the foreclosure sale from December 22, 2025 to January 19, 2026 to enable a more orderly and commercially reasonable sale process, with the company committing to cooperate by facilitating due diligence and access for potential bidders while expressly maintaining its dispute of the alleged defaults and reserving all rights to challenge the sale and related proceedings.

The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Releases Q3 2025 Financial Update

Bioceres Crop Solutions Corp. released its unaudited interim condensed consolidated financial statements for the periods ending September 30, 2025, and June 30, 2025. The financial report indicates a decrease in total assets from $763.6 million to $734.9 million, and a reduction in total liabilities from $468.4 million to $446.5 million. This financial update provides stakeholders with insights into the company’s current financial health and operational adjustments over the recent quarter.

The most recent analyst rating on (BIOX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Reports Q1 2026 Financial Results Amid Strategic Transition

Bioceres Crop Solutions reported its fiscal first quarter 2026 financial results, with total revenues of $77.5 million, marking a 17% decline year-over-year. Despite the revenue drop due to strategic reductions in low-margin sales and seed model transition, the company achieved a gross margin expansion from 40% to 47%, reflecting a more profitable product mix. The net loss widened to $7.5 million, but operating profit and adjusted EBITDA saw significant improvements, driven by cost discipline and restructuring efforts. The company remains focused on enhancing capital structure and financial flexibility amidst challenging market conditions in Argentina.

The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Faces Legal Action Over Alleged Defaults

On November 10, 2025, Bioceres Crop Solutions received an Acceleration Notice from its noteholders, alleging defaults under its Convertible and Non-Convertible Note Purchase Agreements. Subsequently, on November 11, 2025, these noteholders initiated legal proceedings against Bioceres in the New York Supreme Court, seeking full payment of outstanding amounts. Bioceres disputes the allegations and intends to defend its position vigorously, reserving all rights against the noteholders.

The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.

Bioceres Crop Solutions Strengthens Leadership with New Appointments

On November 5, 2025, Bioceres Crop Solutions Corp. announced the appointment of Mr. Simon Vumbaca to its Board of Directors and Mr. Alejandro Villafane as the Principal Accounting Officer. Mr. Vumbaca brings expertise in high-stakes strategies and governance, while Mr. Villafane will oversee the company’s accounting functions. These appointments are expected to strengthen Bioceres’ strategic and financial leadership, potentially enhancing its market position and operational resilience.

The most recent analyst rating on (BIOX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Bioceres Crop Solutions stock, see the BIOX Stock Forecast page.